First-line temozolomide therapy and MGMT status in elderly patients with primary CNS lymphoma
M Glas, D Kurzwelly, P Roth, K Rasch, E Weimann, H Lohner, A Waha, M Stuplich, M Simon, M Schabet, G Reifenberger, M Weller, U Herrlinger · Aktuelle Neurologie · 2009 · Heft 10
Bibliografische Angaben
Zusammenfassung
Objective: This series explores temozolomide monotherapy in elderly patients with primary CNS lymphoma (PCNSL) and severe comorbidities. Patients and methods: We reviewed the charts of four German Medical Centers to identify PCNSL patients treated with primary TMZ chemotherapy, and analyzed toxicity, response to therapy, survival parameters and MGMT promotor methylation status in these patients. Results: In 17 patients (62–90 years old), complete response rate was 47%, median progression-free survival was 5 months and median overall survival was 21 months. Five of 17 patients (29.4%) had prolonged responses for…
